Navigation Links
Celgosivir in Medical News

MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study

VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received preliminary four-week interim results from a Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patie...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...erferon II-58 Nautilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Release...
Celgosivir in Medical Technology

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical res...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

...bination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
Celgosivir in Biological Technology

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") ...

MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Vir...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

...cal study program (previously Cutanea was targeting the end of 2008). celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatiti...e are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions. MX-2401 (IV lipopeptide;...

MIGENIX Corporate Update and Requisition of Special Meeting

...ayments and a single-digit royalty on net sales. celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C ...rus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinet...pment by the end of 2008; to have results from the celgosivir Phase II viral kinetics study in the next several ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

...nt payment(s), milestones and royalty terms celgosivir (hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir viral kinetics study to include a 600 mg celgosivir combination arm (600 mg ...

MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results

...such a partnership(s) is uncertain at this time. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinet... to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of th...

MIGENIX releases CEO message #22

...n H2/08 - NDA submission in H1/09 - Rest of world partnership celgosivir (hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering i...

MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results

...) for omiganan 1% gel in the first half of 2009. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegyl... (SVR). The safety profile for patients exposed to celgosivir for up to 48 weeks did not differ from those in th...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

... Company to Report Interim celgosivir 4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2...

MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... Company Provides Revised Timing on Interim celgosivir Viral Kinetics Study ... prevention of catheter-related infections - celgosivir - a Phase II product candidate for treating chroni...rom a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infectio...
Other Tags
(Date:9/16/2014)... September 16, 2014 Antioch University has ... Arts in Clinical Mental Health Counseling from Antioch ... list of programs offered through Antioch’s online campus. The ... January 2015. , "Antioch University New England’s MA in ... the field and a track record of preparing graduates ...
(Date:9/16/2014)... The rapidly increasing cost of compounded medications has ... PBMs as spending on these specialized drugs has catapulted ... concentrated, patient-specific practice, compounding has become commonplace in the ... Inc. (AIS), “Controlling the Cost of Compounded Medications: ... one leading health insurer and its internal PBM are ...
(Date:9/16/2014)... Madisonville, Louisiana (PRWEB) September 16, 2014 ... packaging for one of its most popular products - ... been designed to educate the general public about the ... weight management and building lean muscle mass. As well ... now detail product benefits, supplement facts, and nutritional information ...
(Date:9/16/2014)... 16, 2014 The Living Ethics lecture ... fall. Reflecting on what it means to live in ... investigates unique and thought-provoking topics. , “The Museum’s job ... to look at their world differently. The Living ... stage for truly enlightening dialogue,” says Richard Conti, Chief ...
(Date:9/16/2014)... September 16, 2014 DiaperBuys, a national ... ‘Healthy Aging’ Month this September. Healthy Aging Month was ... across the nation on the positive aspects of growing ... with conditions or side effects from medications that cause ... Outreach Manager for DiaperBuys.com. “This can seem daunting to ...
Breaking Medicine News(10 mins):Health News:Antioch University Launches Online Master’s Degree Program in Clinical Mental Health Counseling 2Health News:Sept. 25 Webinar to Offer Health Plan, Employer Strategies to Control Compounded Medication Costs 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 3Health News:Expanding Community Vision at the Science Museum of Virginia 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3
(Date:9/15/2014)... West Africa, which has claimed more than 2000 lives, ... the molecular biology of the virus that could be ... to treat or prevent Ebola hemorrhagic fever. Now, a ... under the leadership of Dr Dan Engel, a virologist, ... obtained the crystal structure of a key protein involved ...
(Date:9/15/2014)... long and weighing as much as 170 tons, the blue ... far the heaviest living thing ever seen on Earth. So ... the tiniest fish larvae, which measure millimeters in length and ... , Not so fast, says L. Mahadevan, the Lola ... Evolutionary Biology, and of Physics. , Using simple hydrodynamics, ...
(Date:9/15/2014)... teeming with life it,s not what comes to mind ... time evidence of Doncaster,s 310-million-year-old past, including a fossilised shark ... , Some of the fossilised plants and creatures may even ... case, several horseshoe crabs and some previously unrecorded seed pods ... rocks that formed within the coal and shale deposits in ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2The science behind swimming 2The science behind swimming 3'Jaws' lived in Doncaster 2
Other Contents